Clinical Trial: CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07782827) titled 'CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)' on Aug. 20.

Brief Summary: The primary purpose of the study is to evaluate efficacy of obudanersen in participants with AS due to uniparental disomy or imprinting defects (UPD/ID) as measured through expressive communication.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Angelman Syndrome

Intervention: DRUG: obudanersen

ION582 will be administered by IT injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ionis Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syndicati...